Navigation Links
Lexicon Pharmaceuticals To Present At The Wedbush PacGrow 2012 Management Access Conference
Date:8/10/2012

THE WOODLANDS, Texas, Aug. 10, 2012 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that Arthur Sands, M.D., Ph.D., President and Chief Executive Officer, will present at the Wedbush PacGrow 2012 Life Sciences Management Access Conference on Tuesday, August 14th, at 10:55 AM EST in New York City. Dr. Sands will provide an overview of Lexicon's clinical development programs and milestones.

A webcast of the presentation will be available through Lexicon´s website at www.lexpharma.com. An archived version of the presentation will be available at www.lexpharma.com until September 14th, 2012.

About Lexicon
Lexicon is a biopharmaceutical company focused on discovering breakthrough treatments for human disease. Lexicon currently has four drug programs in mid-stage development for diabetes, carcinoid syndrome, irritable bowel syndrome and rheumatoid arthritis, all of which were discovered by Lexicon's research team. Lexicon has used its proprietary gene knockout technology to identify more than 100 promising drug targets. Lexicon has focused drug discovery efforts on these biologically-validated targets to create its extensive pipeline of clinical and preclinical programs. For additional information about Lexicon and its programs, please visit www.lexpharma.com.

Safe Harbor Statement
This press release contains "forward-looking" statements, including statements relating to Lexicon's growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information.  All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon's ability to successfully conduct preclinical and clinical development of its potential drug candidates, advance additional candidates into preclinical and clinical development, obtain necessary regulatory approvals, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates, that may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward-looking statements.  Information identifying such important factors is contained under "Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2011, as filed with the Securities and Exchange Commission.  Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Lexicon to Provide First Quarter 2012 Financial Results
2. Lexicon Pharmaceuticals Reports On Clinical Program Status And 2012 First Quarter Results
3. Lexicon Receives Funding for Phase 2 Clinical Trial of LX4211 in Type 1 Diabetes
4. Lexicon Pharmaceuticals to present at the Jefferies 2012 Global Healthcare Conference
5. Lexicon Presents Data Regarding the Mechanism of Action and Safety of LX4211 at American Diabetes Association Meeting
6. Lexicon Announces Positive Results of LX4211 Phase 2b Trial For Type 2 Diabetes
7. Lexicon Announces Publication of Results of Two Studies of LX4211 in Patients with Type 2 Diabetes in the Journal Clinical Pharmacology & Therapeutics
8. Lexicon to Provide Second Quarter 2012 Financial Results
9. Lexicon Pharmaceuticals Reports On Clinical Program Status And 2012 Second Quarter Results
10. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
11. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... PRINCETON, New Jersey and OR AKIVA, ... Regentis Biomaterials Ltd., a leader ... of its Series D investment round on February 5, ... Haisco Pharmaceutical Group ("Haisco"), a leading Chinese pharmaceutical ... Medica Partners, SCP Vitalife Partners, Generali Financial Holdings and ...
(Date:2/10/2016)... SAN DIEGO , Feb. 10, 2016 ALSP, ... Hack , MD as Consultant for Medical Affairs in preparation ... Michael Pierschbacher , PhD, CEO, stated, "We are ... team. We look forward to working with an individual of ... (TBI). We look forward to drawing deeply on his broad ...
(Date:2/10/2016)... , February 10, 2016 ... market research report "Pharmaceutical Packaging Equipment Market by Package ... & Serialization), by Product Type (Tablet, Powder, Cream, Syrup, ... by MarketsandMarkets, studies the global market during the forecast period ... grow at a CAGR of 6.9% during the forecast ...
Breaking Medicine Technology:
(Date:2/10/2016)... ... 10, 2016 , ... Western University of Health Sciences and ... developmentally disabled in the Coachella Valley. , The two entities, through an expanded ... Highway 111, Suite 100-B, in Rancho Mirage, California. The new site has 11 ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... (VRI) within Healthcare, recently partnered with Heart City Health Center to ... nearly 23 years, Heart City Health Center has provided the Elkhart community with ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... master charity program created to assist the local community. Pledging to select a ... and nonprofit organizations in the area. Their goal is to bring community awareness ...
(Date:2/10/2016)... ... 10, 2016 , ... Dr. Peyman Ghasri, skin doctor ... variety of comprehensive procedures for facial enhancement. The treatments now available at Castle ... and nasal reshaping. , As a result, patients can improve virtually every ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... ... San Diego, will bring together more than 200 of the country’s top healthcare ... the future. , “The true benefit of the Forum is the provider-centric perspective, ...
Breaking Medicine News(10 mins):